ArticleNeoplasia (New York, N.Y.)2007
Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides.
Article in Neoplasia (New York, N.Y.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- The Extracellular Protein, Transthyretin Is an Oxidative Stress Biomarker.Frontiers in physiology · 2019Article
- Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.Disease markers · 2016Review
- Identification of autoantibodies against transthyretin for the screening and diagnosis of rheumatoid arthritis.PloS one · 2014Article
- Plasma proteomics analysis of tamoxifen resistance in breast cancer.Medical oncology (Northwood, London, England) · 2013Article
- Potential biomarkers in the sera of breast cancer patients from bahawalpur, pakistan.Biomarkers in cancer · 2012Article
- Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).Leukemia · 2010Article
- Challenges for biomarker discovery in body fluids using SELDI-TOF-MS.Journal of biomedicine & biotechnology · 2010Review
- The War on Cancer rages on.Neoplasia (New York, N.Y.) · 2009Article
- A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature.Proteome science · 2008Article
- Neoplasia: the second decade.Neoplasia (New York, N.Y.) · 2008Article
- Neuroproteomics as a promising tool in Parkinson's disease research.Journal of neural transmission (Vienna, Austria : 1996) · 2008Review
- Applications of SELDI-MS technology in oncology.Journal of cellular and molecular medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous T-cell lymphomas (CTCLs) are characterized by the recruitment of malignant T-cell clones, predominantly of the CD4(+) T-helper subpopulation, into the skin. Mycosis fungoides (MF) is the most common type of CTCL and accounts for almost 50% of all primary cutaneous lymphomas. The ProteinChip technology surface-enhanced laser desorption/ionization time of flight/mass spectrometry (SELDI-TOF-MS) was used to detect biomarkers in sera from MF patients (n = 25) and healthy controls (n = 26). Therefore, diluted sera were applied to IMAC30 ProteinChip arrays, and the resulting protein profiles were bioinformatically analyzed. A protein set that distinguishes MF patients from healthy controls with a sensitivity of 82.6% and a specificity of 100% was identified. Four significant peaks were identified by two-dimensional gel electrophoresis, immunodepletion, and SELDI-TOF-MS as transthyretin (TTR) and three TTR modifications. A subsequent enzyme-linked immunosorbent assay confirmed these findings. The ability to detect and identify proteins and protein modifications using SELDI-TOF-MS might reveal a better insight on this kind of disease and may lead to a better understanding and earlier detection of MF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.